Nasdaq ardx.
Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...
Nov 24, 2023 · Who is on Ardelyx's Insider Roster? The list of insiders at Ardelyx includes David M. Mott, David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell, and Susan Rodriguez. Learn more on insiders at ARDX. May 17, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ... WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for …Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 89.08% from the stock’s current price. A number of […]
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.
Ardelyx (NASDAQ: ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...16 thg 8, 2021 ... Ardelyx (NASDAQ:ARDX) is trading higher today on below-average volume despite a loss of over 5% on Friday after the company announced worse ...
May 5, 2023 · Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company based in Waltham, Massachusetts. The company develops and commercialized medicines to treat gastrointestinal and cardiorenal therapeutic ... Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
A high-level overview of Ardelyx, Inc. (ARDX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...
Ardelyx, Inc. Common Stock (ARDX). Nasdaq Listed ...Find the latest news headlines from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Based on analysts offering 12 month price targets for ARDX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Discover historical prices for ARDX stock on Yahoo Finance. View daily, weekly or monthly format back to when Ardelyx, Inc. stock was issued.Ardelyx (NASDAQ: ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy.Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...
Webull offers ARDX Ent Holdg (ARDX) historical stock prices, in-depth market analysis, NASDAQ: ARDX real-time stock quote data, in-depth charts, free ARDX ...Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of …Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...Aug 28, 2023 · Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ... The latest price target for . Ardelyx (NASDAQ: ARDX) was reported by HC Wainwright & Co. on November 1, 2023.The analyst firm set a price target for $11.00 expecting ARDX to rise to within 12 ...Feb 19, 2023 · ARDX stock is up more than 270% in the last six months, and analysts are already projecting more gains down the road. The consensus price target for Ardelyx is $6.87, meaning ARDX stock still has ...
Ardelyx, Inc. (NASDAQ: ARDX): $3.63 per Share. Ardelyx is a biopharmaceutical company focused on developing and commercializing drug candidates that address significant unmet medical needs. Its current product takes a novel approach to treating irritable bowel syndrome. Pipeline products include a small-molecule therapy for …
Oct 11, 2023 · Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ... WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Ardelyx (NASDAQ:ARDX) is scheduled to announce Q4 earnings results on Thursday, March 2nd, after market close.The consensus EPS Estimate is -$0.02 and the consensus Revenue Estimate is $23.18M (vs ...The latest price target for Ardelyx ( NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023. The analyst firm set a price target for 11.00 expecting ARDX to rise to ...Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts.Consensus estimates suggest investors ...ARDX U.S.: Nasdaq Ardelyx Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 4:07 p.m. EST Real time quote $ …Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F …Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ...
Ardelyx Inc. ARDX (U.S.: Nasdaq). AT CLOSE 4:00 PM EST 12/01/23. $4.76USD; 0.25 ... ARDX. Significant News Only. 11/17/22; Barron's. Ardelyx Skyrockets. Its ...
Ardelyx Inc (NASDAQ:ARDX) trade information. Ardelyx Inc (ARDX) registered a 3.20% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.20% in intraday trading to $4.51 this Thursday, 11/30/23, hitting a weekly high. The stock’s 5-day price performance is 4.64%, and it has moved by 14.18% in 30 days.
Ardelyx, Inc. (NASDAQ:ARDX) Number of Hedge Fund Holders: 16 Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that designs and sells treatments for gastrointestinal, heart, and kidney ...Jul 18, 2021 · Ardelyx, Inc. (NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, develops ... 16 thg 8, 2021 ... Ardelyx (NASDAQ:ARDX) is trading higher today on below-average volume despite a loss of over 5% on Friday after the company announced worse ...Mar 3, 2023 · On March 3, 2023, Wedbush upgraded their outlook for Ardelyx (NASDAQ:ARDX) from Neutral to Outperform.. Analyst Price Forecast Suggests 47.30% Upside. As of March 4, 2023, the average one-year ... WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...730% upside stock according to Citigroup Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the …730% upside stock according to Citigroup Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the …Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ...Sean Pavone/iStock via Getty Images. At a Glance. Navigating through robust quarterly sales, particularly from its flagship IBS-C product Ibsrela (tenapanor), Ardelyx (NASDAQ:ARDX) continues to ...Mar 3, 2023 · On March 3, 2023, Wedbush upgraded their outlook for Ardelyx (NASDAQ:ARDX) from Neutral to Outperform.. Analyst Price Forecast Suggests 47.30% Upside. As of March 4, 2023, the average one-year ... 3 Penny Stocks to Buy and Hold for the Next 10 Years. 1 month ago. Simply Wall St. 1 week ago. Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, …
Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and ...Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ...WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Instagram:https://instagram. whole life insurance retirementhsb bankcws etfcalibre mining stock Get Ardelyx Inc. (ARDX) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, financial report, etc.Ardelyx Inc (NASDAQ:ARDX) is the most popular stock in this table. On the other hand Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS ) is the least popular one with only 8 bullish hedge fund positions. trctf6 month treasury bill 5 equities research analysts have issued 12-month price targets for Ardelyx's shares. Their ARDX share price targets range from $7.00 to $11.00. On average, ...Ardelyx Inc (NASDAQ: ARDX) Ardelyx is a biotech penny stock which already has a successful product on the market . Ibsrela (tenapanor) is a drug that was introduced by the company in March 2022. It is used … bot cryptocurrency WALTHAM, Mass., Oct. 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class ...WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Jul 18, 2021 · Ardelyx, Inc. (NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, develops ...